About US
Contact us
-
Ex-staffer pleads guilty to scamming Takeda out of $2.3M through fake consulting firmAfter fessing up to wire fraud charges, a former Takeda employee will be preparing for a sentencing hearing rather than walking down the aisle with $2.3 million garnered through a scheme to defraud t2024/5/21
-
BMS chief Boerner says company is still open to deals after spending more than $20B on M&A last yearAs some pharma giants pump the brakes on big M&A deals, Bristol Myers Squibb—hot off a series of rapid-fire acquisitions in 2023—says it still has dealmaking cash to deploy if the right target co2024/5/21
-
UPDATED: Sanders wants to subpoena Novo Nordisk exec to answer questions on Wegovy, Ozempic pricingSen. Bernie Sanders, I-Vermont, is stepping up his attack on Novo Nordisk over the prices the company charges in the U.S. for its wildly popular diabetes and weight loss drugs. Sanders, the chairman2024/5/16
-
Europe taps CSL Seqirus to produce bird flu vaccines for pandemic preparedness effortsRight after signing on to help with bird flu pandemic preparedness efforts in the U.S., CSL Seqirus has agreed to do the same in Europe through a vaccine supply pact. The European Commission’s Health2024/5/16
-
Ahead of UK election, life sciences trade group pushes politicians to boost local industryAs the U.K. braces for a potential government shake-up ahead of its general election next month, the country’s premier biopharma trade organization is throwing down the gauntlet. The Association of t2024/5/14
-
Gilead forks over $40M to settle thousands of claims in web of litigation over alleged delay of safer HIV medsAs Gilead Sciences awaits the progression of California state litigation over itsalleged delay of safer HIV drugs, the company is bidingits time with a proposed $40 million settlement to quell the cl2024/5/14
-
Ipsen, Genfit gain FDA approval for Iqirvo in liver disorder, teeing up Intercept showdownOnce hyped as a potential blockbuster medicine for metabolic-associated steatohepatitis (MASH), Ipsen and Genfit’s elafibranor has found its calling as a treatment for a lower-profile liver disorder.2024/5/9
-
After M&A stretch, Pfizer CEO says company needs 'breathing period' from large dealsAmid a recent biopharma M&A resurgence, one major player plans to stay out of the waters after making multiple recent splashes. Though not for lack of business development capacity, Pfizer is cur2024/5/9
-
Colorado drug review board finds J&J's Stelara unaffordable, teeing up potential statewide price capColorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lowerprices oncertain drugs starting in 2026. After the board previously voted to2024/5/7
-
GSK notches Zantac win in Illinois, appeals high-stakes setback in DelawareAs the year rolls on, GSK continues to knock out personal injury lawsuits in the long-running legal saga over whether the popular heartburn medication Zantac can cause cancer. Plaintiff Eugenia Kasza2024/5/7